Impact of COVID-19 on the prevalence and burden of MDD

The COVID-19 pandemic had a profound global impact on healthcare systems, as shown by this analysis of the Global Burden of Disease study data.¹

References:

1.GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403 (10440): 2133–2161.

2.COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398 (10312): 1700–1712.

3.Institute for Health Metrics and Evaluation (IHME), 2022. Available at https://vizhub.healthdata.org/gbd-results.